Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608580 | 0.94 | GSK3B (0.53) | GSK3BALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5561006 | 0.87 | SMN1; SMN2 (0.56) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL6517745 | 0.81 | GSK3B (0.68) | GSK3BKMT2ASMN1; SMN2MAPTPTPN1 | |
| SCHEMBL6406510 | 0.79 | MAPT (0.50) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL13545219 | 0.78 | SMN1; SMN2 (0.51) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL4345155 | 0.78 | HTT (0.58) | GSK3BALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL18209648 | 0.76 | GSK3B (0.68) | GSK3BALDH1A1KMT2ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL9863504 | 0.76 | ALDH1A1 (0.49) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL23553765 | 0.75 | MEN1 (0.62) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL30041713 | 0.75 | MEN1 (0.62) | ALDH1A1KMT2ASMN1; SMN2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | GSK3B 4101/4885ALDH1A1 945/4885KMT2A 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.